Screener
Rigel Pharmaceuticals RIGL Delivery of drug supplies, royalties and others — Revenue recognized
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Gross product sales | $75,388 | $60,192 |
| Discounts and allowances | (20,465) | (16,642) |
| Total product sales, net | 54,923 | 43,550 |
| Contract revenues from collaborations: | ||
| Milestone revenue | — | 3,000 |
| Delivery of drug supplies, royalties and others | 3,895 | 6,783 |
| Total contract revenues from collaborations | 3,895 | 9,783 |
| Total revenues | $58,818 | $53,333 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized?
- Rigel Pharmaceuticals (RIGL) reported delivery of drug supplies, royalties and others — revenue recognized of $3.9M in Q1 2026.
- How has Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized changed year-over-year?
- Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized decreased by 42.6% year-over-year, from $6.78M to $3.9M.
- What is the long-term trend for Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized has grown at a 55.0% compound annual growth rate (CAGR), from $3.3M to $19.05M.
- What does delivery of drug supplies, royalties and others — revenue recognized mean?
- This metric represents the revenue recognized from the sale of pharmaceutical products, royalty payments received from licensing agreements, and other related commercial activities. It captures the income generated from the company's core drug portfolio and the monetization of intellectual property through partnerships. This revenue stream is critical for assessing the company's ability to commercialize its pipeline and extract value from collaborative development agreements.
Ask your AI about Rigel Pharmaceuticals's delivery of drug supplies, royalties and others — revenue recognized.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude